MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
P/S ratio for MyMD Pharmaceuticals, Inc. (MYMD)
P/S ratio as of 2023: 0.00
According to MyMD Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2022 the company had a P/S ratio of 0.00.
P/S ratio history for MyMD Pharmaceuticals, Inc. from 2005 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 0.00 |
| 2022 | 0.00 |
| 2021 | 0.00 |
| 2020 | 0.00 |
| 2019 | 1.24 |
| 2018 | 446.71 |
| 2017 | 19.43 |
| 2016 | 209.07 |
| 2015 | 176.46 |
| 2014 | 256.62 |
| 2013 | 147.54 |
| 2012 | 248.21 |
| 2011 | 193.76 |
| 2010 | 79.37 |
| 2009 | 130.42 |
| 2008 | 21.70 |
| 2007 | 23.90 |
| 2006 | 117.82 |
| 2005 | 23.01 |